Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.40 per share
-
Shares outstanding
-
23.6M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
25.3M
-
Shares change
-
+2.45M
-
Total reported value, excl. options
-
$169M
-
Value change
-
+$23.3M
-
Number of buys
-
41
-
Number of sells
-
-27
-
Price
-
$6.64
Significant Holders of Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) as of Q2 2021
81 filings reported holding AUTL - Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share as of Q2 2021.
Autolus Therapeutics plc - Ordinary Shares, par value NIS 0.40 per share (AUTL) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.3M shares
.
Largest 10 shareholders include Capital World Investors (2.96M shares), CITADEL ADVISORS LLC (2.76M shares), Polygon Management Ltd. (2.5M shares), FRAZIER MANAGEMENT LLC (2.28M shares), FMR LLC (2.07M shares), Nantahala Capital Management, LLC (1.79M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (1.67M shares), Ikarian Capital, LLC (1.36M shares), JPMORGAN CHASE & CO (751K shares), and MILLENNIUM MANAGEMENT LLC (725K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.